Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

FULCRUM THERAPEUTICS ($FULC) Releases Q1 2026 Earnings

None

FULCRUM THERAPEUTICS ($FULC) posted quarterly earnings results for Q1 2026 on Monday, April 27th. The company reported earnings of -$0.25 per share, beating estimates of -$0.30 by $0.05. The company also reported revenue of $0, equaling estimates of $0 by $0.

You can see Quiver Quantitative's $FULC stock page to track data on insider trading, hedge fund activity, congressional trading, and more.

EARLY ACCESS
Receive FULC Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

FULCRUM THERAPEUTICS Insider Trading Activity

FULC Insider Trades

FULCRUM THERAPEUTICS insiders have traded $FULC stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

Here’s a breakdown of recent trading of $FULC stock by insiders over the last 6 months:

  • CAPITAL MANAGEMENT, L.P. RA has made 0 purchases and 3 sales selling 4,175,139 shares for an estimated $58,377,021.
  • ROBERT J GOULD has made 0 purchases and 2 sales selling 30,000 shares for an estimated $326,352.
  • CURTIS GALE OLTMANS (Chief Legal Officer) sold 3,452 shares for an estimated $44,599

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

FULCRUM THERAPEUTICS Hedge Fund Activity

We have seen 102 institutional investors add shares of FULCRUM THERAPEUTICS stock to their portfolio, and 62 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

FULCRUM THERAPEUTICS Analyst Ratings

Wall Street analysts have issued reports on $FULC in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • HC Wainwright & Co. issued a "Buy" rating on 11/24/2025
  • Truist Securities issued a "Buy" rating on 11/24/2025
  • Piper Sandler issued a "Overweight" rating on 10/30/2025

To track analyst ratings and price targets for FULCRUM THERAPEUTICS, check out Quiver Quantitative's $FULC forecast page.

FULCRUM THERAPEUTICS Price Targets

Multiple analysts have issued price targets for $FULC recently. We have seen 7 analysts offer price targets for $FULC in the last 6 months, with a median target of $20.0.

Here are some recent targets:

  • An analyst from JP Morgan set a target price of $20.0 on 01/12/2026
  • Gregory Renza from Truist Securities set a target price of $18.0 on 12/11/2025
  • Tazeen Ahmad from B of A Securities set a target price of $7.0 on 12/09/2025
  • Edward Tenthoff from Piper Sandler set a target price of $23.0 on 12/08/2025
  • Andrew S. Fein from HC Wainwright & Co. set a target price of $25.0 on 12/08/2025
  • Luca Issi from RBC Capital set a target price of $10.0 on 12/08/2025
  • Kristen Kluska from Cantor Fitzgerald set a target price of $24.0 on 12/08/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles